Stevanato Group S.p.A Shares Outstanding 2021-2025 | STVN

Stevanato Group S.p.A shares outstanding for the quarter ending March 31, 2025 were 0.273B, a 2.61% increase year-over-year.

  • Stevanato Group S.p.A 2024 shares outstanding were 0.271B, a 2.33% increase from 2023.
  • Stevanato Group S.p.A 2023 shares outstanding were 0.265B, a 0.1% increase from 2022.
  • Stevanato Group S.p.A 2022 shares outstanding were 0.265B, a 4.75% increase from 2021.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.

Stevanato Group S.p.A Shares Outstanding 2021-2025 | STVN

  • Stevanato Group S.p.A 2024 shares outstanding were 0.271B, a 2.33% increase from 2023.
  • Stevanato Group S.p.A 2023 shares outstanding were 0.265B, a 0.1% increase from 2022.
  • Stevanato Group S.p.A 2022 shares outstanding were 0.265B, a 4.75% increase from 2021.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$95B
Zoetis (ZTS)$66.3B
Takeda Pharmaceutical (TAK)$46.8B
Daiichi Sankyo, - (DSNKY)$41.7B
Summit Therapeutics (SMMT)$18.2B
Sandoz Group AG (SDZNY)$17.7B
Merck (MKKGY)$17.2B
Astellas Pharma (ALPMY)$16.9B
Shionogi (SGIOY)$14.1B
United Therapeutics (UTHR)$12.8B
Neurocrine Biosciences (NBIX)$10B
IPSEN (IPSEY)$8.6B
Orion OYJ (ORINY)$8B
Madrigal Pharmaceuticals (MDGL)$6.7B
Corcept Therapeutics (CORT)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$5.8B
Ono Pharmaceutical (OPHLF)$5.5B
Grifols, S.A (GRFS)$4.9B
Ionis Pharmaceuticals (IONS)$4.5B
Soleno Therapeutics (SLNO)$3.2B
Crinetics Pharmaceuticals (CRNX)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.3B
Recursion Pharmaceuticals (RXRX)$2.2B
Hypermarcas (HYPMY)$2.1B
NewAmsterdam Pharma (NAMS)$1.8B
Centessa Pharmaceuticals (CNTA)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.5B
Guardian Pharmacy Services (GRDN)$1.5B
ARS Pharmaceuticals (SPRY)$1.5B